Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

HM Lokhorst; I Schmidt-Wolf; Pieter Sonneveld; Ronnie van der Holt; H Martin; R Barge; U Bertsch; J Schlenzka; G (Gerard) Bos; S Croockewit; S Zweegman; I Breitkreuz; Pauline Joosten; C Scheid; M van Marwijk-Kooy; HJ Salwender; MHJ van Oers; R Schaafsma; R Naumann; H Sinnige; I Blau; G Verhoef; O de Weerdt; P Wijermans; S Wittebol; U Duersen; E Vellenga; H Goldschmidt

doi:10.3324/haematol.11644

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

HM Lokhorst, I Schmidt-Wolf, Pieter Sonneveld, Ronnie van der Holt, H Martin, R Barge, U Bertsch, J Schlenzka, G (Gerard) Bos, S Croockewit, S Zweegman, I Breitkreuz, Pauline Joosten, C Scheid, M van Marwijk-Kooy, HJ Salwender, MHJ van Oers, R Schaafsma, R Naumann, H SinnigeI Blau, G Verhoef, O de Weerdt, P Wijermans, S Wittebol, U Duersen, E Vellenga, H Goldschmidt

Research output: Contribution to journal › Article › Academic › peer-review

133 Citations (Scopus)

Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

Original language	Undefined/Unknown
Pages (from-to)	124-127
Number of pages	4
Journal	Haematologica
Volume	93
Issue number	1
DOIs	https://doi.org/10.3324/haematol.11644
Publication status	Published - 2008

Research programs

EMC MM-02-41-03

Access to Document

10.3324/haematol.11644

Cite this

Lokhorst, HM., Schmidt-Wolf, I., Sonneveld, P., van der Holt, R., Martin, H., Barge, R., Bertsch, U., Schlenzka, J., Bos, G., Croockewit, S., Zweegman, S., Breitkreuz, I., Joosten, P., Scheid, C., van Marwijk-Kooy, M., Salwender, HJ., van Oers, MHJ., Schaafsma, R., Naumann, R., ... Goldschmidt, H. (2008). Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 93(1), 124-127. https://doi.org/10.3324/haematol.11644

@article{79e1e8e9f46845eabfd50159ac36d4a6,

title = "Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma",

abstract = "In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.",

author = "HM Lokhorst and I Schmidt-Wolf and Pieter Sonneveld and {van der Holt}, Ronnie and H Martin and R Barge and U Bertsch and J Schlenzka and Bos, {G (Gerard)} and S Croockewit and S Zweegman and I Breitkreuz and Pauline Joosten and C Scheid and {van Marwijk-Kooy}, M and HJ Salwender and {van Oers}, MHJ and R Schaafsma and R Naumann and H Sinnige and I Blau and G Verhoef and {de Weerdt}, O and P Wijermans and S Wittebol and U Duersen and E Vellenga and H Goldschmidt",

year = "2008",

doi = "10.3324/haematol.11644",

language = "Undefined/Unknown",

volume = "93",

pages = "124--127",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Lokhorst, HM, Schmidt-Wolf, I, Sonneveld, P , van der Holt, R, Martin, H, Barge, R, Bertsch, U, Schlenzka, J, Bos, G, Croockewit, S, Zweegman, S, Breitkreuz, I, Joosten, P, Scheid, C, van Marwijk-Kooy, M, Salwender, HJ, van Oers, MHJ, Schaafsma, R, Naumann, R, Sinnige, H, Blau, I, Verhoef, G, de Weerdt, O, Wijermans, P, Wittebol, S, Duersen, U, Vellenga, E & Goldschmidt, H 2008, 'Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma', Haematologica, vol. 93, no. 1, pp. 124-127. https://doi.org/10.3324/haematol.11644

TY - JOUR

T1 - Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

AU - Lokhorst, HM

AU - Schmidt-Wolf, I

AU - Sonneveld, Pieter

AU - van der Holt, Ronnie

AU - Martin, H

AU - Barge, R

AU - Bertsch, U

AU - Schlenzka, J

AU - Bos, G (Gerard)

AU - Croockewit, S

AU - Zweegman, S

AU - Breitkreuz, I

AU - Joosten, Pauline

AU - Scheid, C

AU - van Marwijk-Kooy, M

AU - Salwender, HJ

AU - van Oers, MHJ

AU - Schaafsma, R

AU - Naumann, R

AU - Sinnige, H

AU - Blau, I

AU - Verhoef, G

AU - de Weerdt, O

AU - Wijermans, P

AU - Wittebol, S

AU - Duersen, U

AU - Vellenga, E

AU - Goldschmidt, H

PY - 2008

Y1 - 2008

N2 - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

AB - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

U2 - 10.3324/haematol.11644

DO - 10.3324/haematol.11644

M3 - Article

C2 - 18166796

SN - 0390-6078

VL - 93

SP - 124

EP - 127

JO - Haematologica

JF - Haematologica

IS - 1

ER -